crizanlizumab
Pronunciation: /krɪˈzænlɪzuːmæb/
Humanized monoclonal antibody that blocks P-selectin to reduce frequency of vaso-occlusive crises in sickle cell disease.
Full Definition
Crizanlizumab is a humanized monoclonal antibody directed against P-selectin, an adhesion molecule involved in the pathogenesis of vaso-occlusive crises in sickle cell disease. By blocking P-selectin-mediated interactions between sickled red blood cells, activated platelets, and endothelial cells, crizanlizumab reduces the frequency of painful crises. It is administered as an intravenous infusion and has been approved for patients 16 years and older with sickle cell disease. The drug represents a novel therapeutic approach targeting the inflammatory cascade rather than hemoglobin polymerization.
Usage
Usage note: Generic name preferred. Include infusion schedule when discussing treatment protocols.
In Context
- "The adolescent patient was started on crizanlizumab infusions every 4 weeks for crisis prevention." — Treatment plan
- "Crizanlizumab significantly reduced the annual rate of vaso-occlusive crises in clinical trials." — Pharmaceutical review